Compare ArcelorMittal SA (MT) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs ResMed Inc. — how do they compare? ArcelorMittal SA trades at $61.32 (market cap $47.06B), while ResMed Inc. trades at $227.51 (market cap $31.78B). The key difference: ArcelorMittal SA is the larger of the two by market cap, and ResMed Inc. pays the higher dividend (1.17%). Which is the better fit depends on your goals — on Pluang, investors hold ArcelorMittal SA for 36 Days and ResMed Inc. for 51 Days on average.
| MT | RMD | |
|---|---|---|
Market Cap | $47.06B | $31.78B |
Volume | 1,545,197 | 1,128,382 |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $277.88 |
52-Week Low | $36.91 | $182.82 |
Typical Hold Time | 36 Days | 51 Days |
Enterprise Value | $56.63B | $31.14B |
Dividend Yield | 0.96% | 1.17% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $61.30, down 5.97% amid bearish technical signals and recent Ukraine plant impairment concerns. The stock shows mixed fundamentals with attractive valuation metrics (P/S 0.76, P/B 0.86) but declining revenue trends from $79.8B in 2022 to $61.4B in 2025. Recent Q2 2026 earnings missed expectations, though management expects stronger second-half performance supported by European demand recovery and strategic investments.
While analyst consensus remains bullish with a $74.33 price target (52% buy ratings), significant risks include ongoing Ukraine operations disruption, $1B impairment charge, and China demand weakness. The current price near support levels presents potential entry point for value investors, but requires careful monitoring of European recovery execution and geopolitical stability.
ResMed (RMD) trades at $225.98, up 2.4% today, with a bullish technical outlook supported by moving averages and strong fundamentals. The company reported revenue of $5.15B in 2025, with net income of $1.40B and robust margins. Recent earnings beats and a dividend announcement highlight operational strength, while analyst consensus leans positive with a $242.70 price target.
Outlook remains favorable due to consistent EPS growth and market share gains, though risks include competitive pressures and ongoing legal investigations. The stock offers growth potential from healthcare demand tailwinds, but investors should monitor execution against guidance and macroeconomic factors affecting medical device spending.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
